Search
The U.S. government is contemplating a five-year pilot initiative that would grant certain obese Medicare and Medicaid beneficiaries access to GLP-1 weight loss medications, including Ozempic and Wegovy, for the purpose of managing their weight. According to official documents, Medicaid programs across various states and Medicare Part D insurance plans will have the discretion to opt-in for coverage of these drugs. The pilot program is anticipated to kick off with Medicaid plans in April 2026 and subsequently extend to Medicare plans in January 2027. Clinical trials have demonstrated that these medications can lead to a 15% to 20% reduction in body weight; however, their average annual cost ranges from $5,000 to $7,000, sparking concerns about potential long-term financial implications.
-
C114 Communication Network -
Communication Home
